NCT06369675View on ClinicalTrials.gov

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

PHASE1CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

November 14, 2017

Study Completion Date

November 14, 2017

Conditions

Erythema

Interventions

DRUG

MOB015B

Topical formulation

DRUG

0.2% SLS

Positive control

DRUG

0.9% Saline

Negative control

DRUG

MOB015B vehicle

Topical formulation

Trial Locations (1)

07410

TKL Research, Inc, Fair Lawn

Sponsors

Lead Sponsor

Moberg Pharma AB

All Listed Sponsors

lead

Moberg Pharma AB

INDUSTRY